Episode 3
Victor Bustos, Refoxy Pharma
Why does the perception of facts matter when talking to investors?
How do you attract a US-based chair to a European company’s board?
And what are the advantages of running a virtual biotech with no labs of its own?
Today, I’m joined by Victor Bustos, CEO of Refoxy Pharma. Refoxy is a "virtual biotech" located in Cologne, Germany, and is developing small-molecule drugs for the treatment of age-related disease.
About LifeScience ORG
It’s no secret that Europe is a global leader in generating translational science. We’re grateful at LifeScience ORG to have a community of over 400 life science CEOs – leaders driving change in biotech, medtech, techBio and healthcare.
The conversations inside our community – stories of conviction, navigating challenges, and making bold decisions – inspire us every week. To hear the stories, lessons, and experiences of our life science leaders, listen to A Call to Lead @ LifeScience ORG, available on all good podcasting platforms.
Timestamps:
0:00 - Introduction: The Leadership Journey
1:24 - From Academia to Entrepreneurship
6:00 - Early Leadership Challenges: Truth vs. Perception
7:24 - Communication Skills & Stakeholder Management
10:37 - Peer Learning & Strategic Thinking
12:05 - Building Your Board: Attracting US Talent to Europe
13:29 - Virtual Biotech Model: Advantages & Strategy
16:26 - Due Diligence in CRO Partnerships
18:09 - The Science: Targeting Age-Related Disease
20:01 - Strategic Indication Selection: IPF Case Study
22:01 - Ecosystem Collaboration & Regulatory Landscape
23:31 - The Future of Longevity Medicine
25:25 - Leadership Philosophy: Leading by Example
